ADAPTIMMUNE THERAPEUTICS PLC - AMERICAN DEPOSITARY

Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

26 يناير 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells

12 نوفمبر 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS

11 نوفمبر 2021 09:00:00 بحسب Nasdaq GlobeNewswire

Adaptimmune Reports Third Quarter Financial Results and Business Update

04 نوفمبر 2021 07:30:01 بحسب Nasdaq GlobeNewswire

Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021

21 أكتوبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings

05 أكتوبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial

13 سبتمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies

07 سبتمبر 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

05 سبتمبر 2021 06:15:00 بحسب Nasdaq GlobeNewswire

Adaptimmune Reports Second Quarter Financial Results and Business Update

09 أغسطس 2021 16:00:00 بحسب Nasdaq GlobeNewswire

Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021

28 يوليو 2021 08:11:31 بحسب Nasdaq GlobeNewswire

Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial

19 مايو 2021 17:00:00 بحسب Nasdaq GlobeNewswire

First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

11 مايو 2021 08:00:02 بحسب Nasdaq GlobeNewswire

Adaptimmune Reports First Quarter Financial Results and Business Update

06 مايو 2021 07:30:01 بحسب Nasdaq GlobeNewswire

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

27 أبريل 2021 16:30:00 بحسب Nasdaq GlobeNewswire

Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

22 أبريل 2021 08:00:02 بحسب Nasdaq GlobeNewswire

Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update

25 فبراير 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021

11 فبراير 2021 08:00:02 بحسب Nasdaq GlobeNewswire